Abstract
To improve the pharmacological profile of tumor necrosis factor alpha (TNF-α), we have synthesized a new PEGylated prodrug, PEG-vcTNF-α, using a cathepsin B-sensitive dipeptide (valine-citrulline, vc) to link branched PEG and TNF-α. PEG-modified TNF-α without the dipeptide linker (PEG-TNF-α) and unconjugated TNF-α were also tested as controls. It was found for the first time that TNF-α released from PEG-vcTNF-α was specifically dependent on the presence of cathepsin B. PEG-vcTNF-α induced higher cytotoxicity and greater apoptosis against L929 murine fibrosarcoma cells than PEG-TNF-α. Reversal of these effects by a cathepsin-B inhibitor confirmed that these effects were mediated by cathepsin B-specific release of TNF-α. In vivo pharmacokinetics studies demonstrated that the plasma stability of PEG-vcTNF-α was significantly increased compared to TNF-α. Finally, the improved anticancer efficacy of PEG-vcTNF-α and the distinct activities among the three formulations confirmed the positive contribution of both PEGylation and the dipeptide linkage to the improved drug-like properties of PEG-vcTNF-α. The results here indicate that linking proteins and PEG via the cathepsin B-sensitive dipeptide may be a promising strategy for developing protein therapeutics.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Carswell E A, Old L J, Kassel R L, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA, 1975, 72: 3666–3670, 1:STN:280:DyaE28%2FltlWrtg%3D%3D, 10.1073/pnas.72.9.3666, 1103152
Debs R J, Fuchs H J, Philip R, et al. Immunomodulatory and toxic effects of free and liposome-encapsulated tumor necrosis factor alpha in rats. Cancer Res, 1990, 50: 375–380, 1:CAS:528:DyaK3cXhtFOjsrw%3D, 2295077
Leist M, Jaattela M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol, 2001, 2: 589–598, 1:CAS:528:DC%2BD3MXlvVOqs78%3D, 10.1038/35085008, 11483992
Blick M, Sherwin S A, Rosenblum M, et al. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res, 1987, 47: 2986–2989, 1:STN:280:DyaL2s7oslWruw%3D%3D, 3567916
Creaven P J, Plager J E, Dupere S, et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemoth Pharm, 1987, 20: 137–144, 1:STN:280:DyaL1c%2FislCrsA%3D%3D
Kimura K, Taguchi T, Urushizaki I, et al. Phase I study of recombinant human tumor necrosis factor. Cancer Chemoth Pharm, 1987, 20: 223–229, 1:STN:280:DyaL1c%2FltlWgtA%3D%3D, 10.1007/BF00570490
Sherman M L, Spriggs D R, Arthur K A, et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol, 1988, 6: 344–350, 1:CAS:528:DyaL1cXhsVymu70%3D, 3339398
Chapman P B, Lester T J, Casper E S, et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol, 1987, 5: 1942–1951, 1:STN:280:DyaL1c%2FmtFGjug%3D%3D, 3681377
Rosenberg S A, Lotze M T, Muul L M, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med, 1987, 316: 889–897, 1:STN:280:DyaL2s7ksVGitA%3D%3D, 10.1056/NEJM198704093161501, 3493432
Caliceti P, Veronese F M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev, 2003, 55: 1261–1277, 1:CAS:528:DC%2BD3sXnt1yqsb0%3D, 10.1016/S0169-409X(03)00108-X, 14499706
Wang Y S, Youngster S, Grace M, et al. Structural and biological characterization of PEGylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev, 2002, 54: 547–570, 1:CAS:528:DC%2BD38XktFKhsr8%3D, 10.1016/S0169-409X(02)00027-3, 12052714
Kozlowski A, Harris J M. Improvements in protein PEGylation: PEGylated interferons for treatment of hepatitis C. J Control Release, 2001, 72: 217–224, 1:CAS:528:DC%2BD3MXktVGks7k%3D, 10.1016/S0168-3659(01)00277-2, 11390000
Yoshioka Y, Tsutsumi Y, Ikemizu S, et al. Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency. Biochem Bioph Res Co, 2004, 315: 808–814, 1:CAS:528:DC%2BD2cXhsFWmsbY%3D, 10.1016/j.bbrc.2004.01.125
Yamamoto Y, Tsutsumi Y, Yoshioka Y, et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotech, 2003, 21: 546–552, 1:CAS:528:DC%2BD3sXjt1OnsL0%3D, 10.1038/nbt812
Wu X, Li X, Zeng Y, et al. Site-directed PEGylation of human basic fibroblast growth factor. Protein Expres Purif, 2006, 48: 24–27, 1:CAS:528:DC%2BD28XltFCntbc%3D, 10.1016/j.pep.2006.02.002
Otto H H, Schirmeister T. Cysteine proteases and their inhibitors. Chem Rev 1997, 97: 133–172, 1:CAS:528:DyaK2sXktFOhsA%3D%3D, 10.1021/cr950025u, 11848867
Devetzi M, Scorilas A, Tsiambas E, et al. Cathepsin B protein levels in endometrial cancer: Potential value as a tumour biomarker. Gynecol Oncol, 2009, 112: 531–536, 1:CAS:528:DC%2BD1MXisVOiu70%3D, 10.1016/j.ygyno.2008.10.030, 19110306
Hashimoto Y, Kakegawa H, Narita Y, et al. Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem Bioph Res Co, 2001, 283: 334–339, 1:CAS:528:DC%2BD3MXjtVCmtr0%3D, 10.1006/bbrc.2001.4787
Barrett A J, Kembhavi A A, Brown M A, et al. L-trans-Epoxysuccinyl-leucylamido (4-guanidino) butane (E-64) and its analogues as inhibitors of cysteine proteases including cathepsins B, H and L. Biochem J, 1982, 201: 189–198, 1:CAS:528:DyaL38XhvFGksr0%3D, 7044372
Francisco J A, Cerveny C G, Meyer D L, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood, 2003, 102: 1458–1465, 1:CAS:528:DC%2BD3sXmsFWktL8%3D, 10.1182/blood-2003-01-0039, 12714494
Afar D E H, Bhaskar V, Ibsen E, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther, 2004, 3: 921–932, 1:CAS:528:DC%2BD2cXmtleksLo%3D, 15299075
Dubowchik G M, Firestone R A, Padilla L, et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem, 2002, 13: 855–869, 1:CAS:528:DC%2BD38XksFentr8%3D, 10.1021/bc025536j, 12121142
Sanderson R J, Hering M A, James S F, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res, 2005, 11: 843–852, 1:CAS:528:DC%2BD2MXislWgu7s%3D, 15701875
Doronina S O, Toki B E, Torgov M Y, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotech, 2003, 21: 778–784, 1:CAS:528:DC%2BD3sXkvFertLc%3D, 10.1038/nbt832
Ajaj K A, Biniossek M L, Kratz F. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs. Bioconjug Chem, 2009, 20: 390–396, 1:CAS:528:DC%2BD1MXns1OnsA%3D%3D, 10.1021/bc800429q, 19199576
Stocks S J, Jones A J M, Ramey C W, et al. A fluorometric assay of the degree of modification of protein primary amines with polyethylene glycol. Anal Biochem, 1986, 154: 232–234, 1:CAS:528:DyaL28Xhs1Cls7s%3D, 10.1016/0003-2697(86)90520-8, 3706727
Yamazaki S, Onishi E, Enami K, et al. Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. Jpn J Med Sci Biol, 1986, 39: 105–118, 1:CAS:528:DyaL2sXhs1KgsA%3D%3D, 3784109
Faure M P, Gaudreau P, Shaw I, et al. Synthesis of a biologically active fluorescent probe for labeling neurotensin receptors. J Biol Chem, 1994, 42: 755–763, 1:CAS:528:DyaK2cXkt1Ojtrk%3D
Aniento F, Roche E, Cuervo A M, et al. Uptake and degradation of glyceraldehyde-3-phosphate dehydrogenase by rat liver lysosomes. J Biol Chem, 1993, 268: 10463–10470, 1:CAS:528:DyaK3sXks1Gku78%3D, 8486700
Murata M, Miyashita S, Yokoo C, et al. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett, 1991, 280: 307–310, 1:CAS:528:DyaK3MXkt1Cqs7g%3D
Barrett A J, Kirschke H. Cathepsin B, Cathepsin H, and Cathepsin L. Methods Enzymol, 1981, 80: 535–561, 1:CAS:528:DyaL38XitFejsLw%3D, 10.1016/S0076-6879(81)80043-2, 7043200
Tsutsumi Y, Kihira T, Tsunoda S, et al. Molecular design of hybrid tumor necrosis factor-alpha III: Polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation. J Pharmacol Exp Ther, 1996, 278: 1006–1011, 1:CAS:528:DyaK28XmtVSjs7s%3D, 8819479
Satoh T, Hosokawa M. The mammalian carboxylesterases: From molecules to functions. Annu Rev Pharmacol Toxicol, 1998, 38: 257–288, 1:CAS:528:DyaK1cXivF2itLc%3D, 10.1146/annurev.pharmtox.38.1.257, 9597156
Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen consumption and tissue oxygenation of human tumors. Adv Exp Med Biol, 1990, 277: 895–905, 1:STN:280:DyaK3M3mtlyluw%3D%3D, 2096691
Mahajan S S, Hou L, Doneanu C, et al. Optimization of bivalent glutathione S-transferase inhibitors by combinatorial linker design. J Am Chem Soc, 2006, 128, 8615–8625, 1:CAS:528:DC%2BD28XlvFensb8%3D, 10.1021/ja061766n, 16802828
Vasey P A, Kaye S B, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res, 1999, 5: 83–94, 1:CAS:528:DyaK1MXhtVShtLs%3D, 9918206
Yokoyama M, Okano T, Sakurai Y, et al. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res, 1991, 51: 3229–3236, 1:CAS:528:DyaK3MXkslyku7s%3D, 2039998
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Dai, C., Fu, Y., Li, B. et al. Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma. Sci. China Life Sci. 54, 128–138 (2011). https://doi.org/10.1007/s11427-010-4124-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-010-4124-z